Sun Pharma Q1 FY27: Sales up 10.1%, PAT ₹28,948m

Key takeaway from the June 2026 quarter

Sun Pharmaceutical Industries Ltd reported its consolidated results for the quarter ended June 30, 2026 (Q1 FY27), showing double-digit revenue growth led by India formulations and steady performance in its global portfolio. Consolidated sales were reported at ₹151,836 million, up 10.1% year-on-year. Net profit for the quarter was ₹28,948 million, which multiple reports pegged as a 27% year-on-year rise. The company also reported EBITDA of ₹44,177 million, up 2.7% year-on-year, with an EBITDA margin of 28.9%.

Market expectations were mixed versus the reported numbers, with profit missing a CNBC-TV18 poll estimate even as EBITDA was ahead of the estimate. The quarter also included an exceptional charge that influenced reported profitability. Overall, the update offers investors a clean read on domestic growth, margin trajectory, and the cost impact from one-off items.

Consolidated sales growth and operating performance

Sun Pharma’s Q1 FY27 consolidated sales stood at ₹151,836 million, reflecting a 10.1% year-on-year increase. Another reported cut of the same period put revenue from operations at ₹152,998.8 million, up about 10.5% year-on-year, indicating a similar growth picture depending on classification and inclusion of other operating income. The company also reported that sales excluding other operating revenue grew 10.1% to ₹151,836 million.

EBITDA came in at ₹44,177 million, up 2.7% year-on-year, and the EBITDA margin was reported at 28.9%. Gross margin improved to 80.5%, attributed to a better product mix. These metrics suggest that operating leverage from higher sales was partly offset by costs, even as the product mix supported gross profitability.

Profitability: reported PAT, adjusted profit, and what changed

Net profit for Q1 FY27 was ₹28,948 million. Separate coverage of the same quarter described the result as a 27% year-on-year increase in consolidated net profit attributable to owners, with the year-ago comparable at ₹22,786.3 million. Sequentially, one report said profit rose 6.7% from ₹27,140.3 million in the March quarter.

Adjusted net profit was reported at ₹30,894 million, up 3.1% year-on-year. This gap between reported and adjusted profit was linked to exceptional items booked during the quarter. Profit before exceptional items and tax was reported at ₹43,029 million, while profit before tax after exceptional items was ₹40,988.1 million, alongside disclosed exceptional charges.

Exceptional charge: Organon acquisition costs and labour codes

The quarter’s reported profit included an exceptional charge of ₹2,040.9 million. This exceptional item comprised ₹1,670 million of acquisition-related costs linked to the proposed acquisition of Organon, and ₹370 million related to implementation of India’s new labour codes. The disclosure is relevant for investors comparing reported profit versus underlying performance, especially when benchmarking to poll estimates.

India formulations: fastest-growing driver in the quarter

India formulations sales increased 16% year-on-year to ₹54,749 million. The company said India formulation sales accounted for 36.1% of total consolidated sales, reinforcing the domestic market’s weight in the overall mix. During Q1 FY27, Sun Pharma launched five new products in the Indian market.

Another reported detail said Sun Pharma became the number two generic semaglutide injectable player and held an 8.5% market share in the Indian pharmaceutical market. While the quarter’s results statement emphasised broad-based India growth, these additional metrics point to competitive positioning in key therapy areas.

Global footprint: US, emerging markets, and rest of world

For Q1 FY27, U.S. Formulations sales were reported at US$427 million. Emerging Markets contributed US$ 311 million, up 4.2%, while Rest of World Formulations recorded sales of US$ 218 million. These figures provide a snapshot of geographic diversification alongside India’s growth, although the article’s primary focus remained on consolidated performance and the domestic formulations momentum.

Street expectations: what beat estimates and what missed

According to a CNBC-TV18 poll referenced in the coverage, net profit missed expectations. The poll estimate for profit was ₹30,510 million versus the reported ₹28,948 million. On the revenue line, consolidated revenue from operations was reported at ₹152,998.8 million, below the CNBC-TV18 estimate of ₹156,250 million.

At the operating level, EBITDA was reported at ₹44,177 million, ahead of the CNBC-TV18 estimate of ₹42,550 million. This combination of EBITDA outperformance and profit miss aligns with the quarter’s exceptional charge and the mix of operating versus below-the-line impacts.

R&D spending and investment intensity

Sun Pharma reported R&D investment of ₹8,264 million during Q1 FY27. The company said this was 5.4% of sales. The disclosure ties R&D intensity to the quarter’s revenue scale and provides a consistent yardstick for comparing investment levels across periods.

Summary table: key reported numbers for Q1 FY27

Segment snapshot table: sales mix reported in the quarter

Why the quarter matters for investors

The Q1 FY27 update highlights a familiar shape to Sun Pharma’s recent performance: strong domestic formulations growth and steady consolidated expansion, alongside a margin profile that remained largely stable at the EBITDA level. The improved gross margin to 80.5% signals the importance of product mix, even as the EBITDA growth rate trailed sales growth.

The other key investor lens is the quality of earnings. With an exceptional charge of ₹2,040.9 million, the gap between reported net profit (₹28,948 million) and adjusted net profit (₹30,894 million) becomes central to interpreting the quarter and comparing it with consensus expectations.

Conclusion

Sun Pharma’s Q1 FY27 results showed consolidated sales of ₹151,836 million and net profit of ₹28,948 million, with India formulations up 16% and EBITDA margin at 28.9%. The quarter also reflected a ₹2,040.9 million exceptional charge tied to Organon acquisition-related costs and labour code implementation. Investors will likely track subsequent updates on the proposed Organon acquisition, along with the sustainability of India growth and the trajectory of margins and R&D intensity in coming quarters.